ORKANews Brief
UPDATE April 29: Oruka upsized and priced its follow-on at roughly $700mn gross, selling 9.66mn shares at $72.50 — well above the $500mn figure cited in the original article. The larger raise extends ORKA's cash runway materially further than previously modeled, but at the cost of incremental dilution shareholders should now factor into per-share valuation work. Separately, BTIG lifted its price target by 94% after the psoriasis readout, a notable endorsement that tightens the bull case around ORKA-001's commercial profile and dosing differentiation. The combination — fully funded balance sheet plus a sell-side reset on the upside — shifts the risk/reward closer to execution risk than financing risk, which was a key overhang flagged in our initial write-up. Watch the next 10-Q for the updated pro-forma cash balance and implied runway in quarters, and track whether other covering analysts follow BTIG's target hike or stay anchored to pre-readout models. Sustained sell-side revisions, rather than a single print, will determine whether the re-rating holds.

Oruka Therapeutics Stock Hits Record High on Psoriasis Drug Data, Then Launches $500M Offering

Oruka Therapeutics (ORKA) surged over 21% to a record high, then immediately filed a $500M stock offering to cash in.

Oruka Therapeutics, Inc. (ORKA) — stock analysis
The numbers
  • ORKA-001 Phase IIa trial hit 64% skin clearance in plaque psoriasis patients
  • Company filed a $500M underwritten offering with a $75M greenshoe option, up to $575M total
  • Guggenheim set a $200 price target; BTIG raised its target by 94%

What Actually Happened

Oruka's lead drug, ORKA-001, is a half-life extended IL-23p19 inhibitor designed for once-yearly dosing. That dosing schedule is the entire investment case. The IL-23 class already dominates psoriasis treatment — AbbVie's Skyrizi alone did over $10bn in 2025 sales. But Skyrizi and its competitors require injections every 8 to 12 weeks. Once a year would be a step change in patient convenience.

The 64% skin clearance from Phase IIa is the first clinical proof that extended dosing might work. Analysts moved quickly. Guggenheim slapped a $200 price target on a $76 stock. BTIG nearly doubled its target. Wall Street read this as best-in-class data, and the stock priced it in same-day.

Then came the capital raise. Within days of the record high, Oruka filed a $500M underwritten public offering with a $75M greenshoe — up to $575M total. That is an enormous raise for a company with no revenue and a negative forward P/E of -28.7x. Management saw the window and jumped through it.

The Catch

Phase IIa is early. Critically early. These trials use small patient groups to show a signal, not prove efficacy at the level regulators demand. The 64% clearance number faces much tougher scrutiny in Phase IIb/III. Larger patient populations and longer follow-up periods tend to humble early results. Plenty of promising Phase IIa psoriasis drugs have stumbled later.

The $575M raise also dilutes existing shareholders at what could be peak enthusiasm. If you bought ORKA before the data and are sitting on a 21% gain, consider what management just signaled: they think the stock is expensive enough to sell a lot of it. Weigh that against the analyst upgrades.

Bottom Line

The science is genuinely interesting. Once-yearly dosing in a $30bn+ psoriasis market would be a category-defining product — if it holds up. But "if it holds up" is doing a lot of work in that sentence. The stock is priced for a future still two or three clinical readouts away. The company just diluted shareholders to fund the path there.

The next catalysts: Phase IIb/III initiation timeline and durability data from extended follow-up. Those will determine whether ORKA-001 is a real threat to Skyrizi or a clean Phase IIa story that faded in later trials.

Want a full financial breakdown on Oruka Therapeutics? Generate a free ORKA report on Basis Report.

Basis Report does not hold positions in securities discussed. This is not investment advice.

Sources & filings